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Neonatal invasive disease due to Streptococcus agalactiae is life threatening and preventive 
strategies suitable for resource limited settings are urgently needed. Protective coverage of 
vaccine candidates based on capsular epitopes will relate to local epidemiology of S. agalactiae 
serotypes and successful management of critical infections depends on timely therapy with effective 
antibiotics. This is the first report on serotype distribution and antimicrobial susceptibility of S. 
agalactiae in pregnant women from a Central African region. Serotypes V, III, and Ib accounted for 
88/109 (81%) serotypes and all isolates were susceptible to penicillin and clindamycin while 13% 
showed intermediate susceptibility to erythromycin.
Neonatal invasive disease due to Streptococcus agalactiae is a life threatening infection. In industrialized 
countries prenatal screening in pregnant women and intra-partum antibiotic prophylaxis (IAP) have 
been widely established and successfully reduced the incidence of newborn morbidity and mortality 
related to S. agalactiae1,2. In low income settings recto-vaginal colonization rates with S. agalactiae in 
pregnant women are similar3; however, screening and IAP for prevention of invasive neonatal disease 
is mostly not implemented due to limitations in resources and infrastructure. Vaccination of pregnant 
women is an alternative prevention strategy that proved effective for other neonatal infectious diseases 
(i.e. neonatal tetanus), and several S. agalactiae vaccine candidates are currently in pre-clinical and clin-
ical development4. Ten capsular polysaccharides have been identified as important virulence factors of 
S. agalactiae and differentiate S. agalactiae into ten distinct serotypes. Based on serotype pathogenicity 
and prevalence, a trivalent polysaccharide-protein conjugate vaccine composed of capsular epitopes from 
serotypes Ia, Ib and III is in Phase II evaluation (NCT02046148); protective coverage will depend on 
selected S. agalactiae serotypes and S. agalactiae serotype distribution in target populations. In case of 
critical infections due to S. agalactiae effective management will depend on timely therapy with antibiot-
ics to which S. agalactiae is sensitive. There is a lack of knowledge on the epidemiology of S. agalactiae 
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in pregnant women from Central sub-Saharan Africa. The aim of this study was to describe serotype 
distribution and antimicrobial susceptibility of S. agalactiae in pregnant women from Gabon.
Methods
Serotypes and antibiotic susceptibility of S. agalactiae isolates from HIV-negative pregnant women 
participating in a multicentre randomized controlled clinical trial comparing the safety and efficacy of 
mefloquine and sulfadoxine-pyrimethamine for intermittent preventive treatment for malaria in preg-
nancy (IPTp) in Gabon (MIPPAD trial; NCT 00811421, registration date December 18, 2008) were stud-
ied. Detailed information on study design, methods, clinical data and outcomes has been published 
recently5,6; the study protocol was approved by the CERMEL institutional ethics review board and all 
experiments were carried out in accordance with international regulations including the Declaration 
of Helsinki . In summary, recto-vaginal swabs were taken at presentation for delivery; nylon flocked 
swabs were used and submerged into Amies transport medium; Lim Broth was inoculated, incubated at 
37 °C and then sub-cultured on Granada agar under aerobic conditions at 37 °C for 24 h; yellow-orange 
pigmented colonies on Granada agar confirmed growth of S. agalactiae. After storage at − 20 °Celsius 
isolates were re-cultured on 5% sheep blood agar and serotypes of the capsular polysaccharides Ia, Ib, 
II-IX were determined by latex agglutination (Strep-B-latex kit; Article 54991/Lot La-1-4, Statens Serum 
Institute, Denmark) according to the manufacturer’s instructions. Isolates were additionally confirmed 
by S. agalactiae multiplex PCR as described by Creti et al.7. Antibiotic drug susceptibility testing was 
performed on horse blood agar plates (MHF, BioMérieux® ). Disc diffusion test was performed with 
erythromycin (15 μ g), clindamycin (2 μ g), cefotaxim (30 μ g), vancomycin (5 μ g), and linezolid (10 μ g). 
gMIC determination was performed as E-Test (BioMérieux® ) for benzylpenicillin, cefalotin, cefotaxim 
and gentamicin; isolates were screened for the presence of high-level gentamicin resistance (HLGR, MIC 
> 500 mg/L). Isolates with intermediate susceptibility to erythromycin were investigated for inducible 
clindamycin resistance by double disc diffusion test (DDT). Disc diffusion tests and gMIC determination 
were performed and interpreted according to the EUCAST (www.eucast.org) guidelines.
Results and Discussion
The prevalence of maternal S. agalactiae colonization at delivery has been reported by Capan-Melser et al.  
and was 19% (106/549; 95% CI 16–23%); S. agalactiae colonization was unrelated to IPTp and illiter-
acy was the only factor associated with higher colonization rates5. One hundred and nine S. agalactiae 
isolates were available for serotyping and antibiotic resistance testing. Serotyping by latex agglutination 
test and PCR was congruent and there was no non-typeable isolate. Almost a third (33/109, 30.3%) of 
isolates were serotype V; second most prevalent was serotype III (30/109, 27.5%), followed by serotype 
Ib (25/109, 22.9%), serotype Ia (14/109, 12.8%), and serotype II (7/109, 6.4%) (Table  1). No serotypes 
IV, VI, VII, XIII or XI were identified.
Serotype distribution varies between countries. Serotype V as most common serotype has been 
reported from The Gambia8 and Egypt9 as well, while in South Africa and Morocco serotypes Ia and 
III dominated with around 30–40% and serotype V represented only around 10% of isolates10–12. Two 
studies from Zimbabwe found serotypes III, V and Ia to be the most prevalent serotypes in decreas-
ing order13,14. Importantly, one study from South Africa did not find significant differences in serotype 
distribution between vaginal and newborn colonizing isolates, but serotype distribution of invasive S. 
agalactiae isolates were significantly different to that of colonizing isolates11. Therefore, in the light of 
development of serotype-based vaccines, studies on invasive isolates are crucial. In a systematic review 
and meta-analysis on S. agalactiae disease in infants aged < 3 months no low-income country was 
represented in the serotype assessment due to lack of data; the most frequently identified serotype in 
all regions with available data was serotype III (48.9%) followed by serotypes Ia (22.9%), Ib (7.0%), II 
(6.2%), and V (9.1%), and five serotypes (Ia, Ib, II, III, V) accounted for > 85% of all serotypes15. Limited 
data on molecular characteristics of African GBS isolates suggests that the overall population structure 
is similar to industrialized countries16–18.
In this study, by disc diffusion test evaluation, all isolates were susceptible to clindamycin, cefotaxim, 
linezolid and vancomycin. Fourteen (13%) isolates showed intermediate susceptibility to erythromy-
cin (Table  2); for these isolates no inducible clindamycin resistance was found by DDT. By E-test, no 
resistance to benzylpenicilline, cefotaxim, and cefalotin, and no high level gentamicin resistance were 






Table 1. Serotype distribution of S. agalactiae isolates.
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observed (Table 2). Whereas various studies in Asia, Europe and the United States have found a signifi-
cant association between serotype V and macrolide resistance, it is remarkable that this association was 
not found in our cohort (Fisher’s Exact Test).
S. agalactiae has been regarded universally susceptible to penicillins and these are the antibiotics of 
first choice for the treatment of S. agalactiae infections. Data of this study confirm susceptibility of S. 
agalactiae to penicillins also for this setting; however, evidence of S. agalactiae with reduced penicillin 
susceptibility and additional resistance to other antibiotic drug classes is increasing19–21 and also reported 
from the African continent22,23 underlining the importance of continuous surveillance to guide empiric 
treatment. Erythromycin is commonly used in case of allergy to penicillins but varying rates of eryth-
romycin resistance are reported by most studies evaluating its susceptibility. In this study intermediate 
susceptibility for erythromycin was seen in 13%, a rate that has also been reported for other sub-Saharan 
African settings22,23. As all isolates were susceptible to clindamycin in this study; clindamycin may there-
fore be a more suitable second-line antibiotic for S. agalactiae infections than erythromycin in this set-
ting. The absence of high level gentamicin resistance supports the recommendation that neonates with 
suspicion of sepsis or meningitis should be treated with the combination of ampicillin and gentamicin.
In conclusion, S. agalactiae isolates colonizing pregnant women in Gabon showed a serotype distribu-
tion in line with other reports from Africa and a susceptibility profile suggesting penicillins as first-line 
and clindamycin as alternative antibiotic for infections due to S. agalactiae.
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(%) MIC Range (MIC50)
E-Test (MIC (mg/L))
Benzylpenicillin S > 0.25, R < 0.25 109 (100) 0 0 0,016;0,19 (0.064)
Cefalotin S > 0.25, R < 0.25 109 (100) 0 0 0.032;019 (0.125)
Cefotaxim S > 0.25, R < 0.25 109 (100) 0 0 < 0.016;0.064 (0.047)
Gentamicin HLGR > 500mg/l No HLGR 2;256 (48)
Disc diffusion test (Zone diameter (mm))
Erythromycin (15μ g) S > 21, I 18–20, R ≤ 17 95 (87.2) 14 (12.8) 0 –
Vancomycin (5μ g) S > 13, R < 13 109 (100) NA 0 –
Linezolid (10μ g) S > 19, I 16–18, R < 15 109 (100) 0 0 –
Clindamycin (2μ g) S > 17, R < 17 109 (100) NA 0 –
Table 2. Antimicrobial susceptibility of S. agalactiae isolates (Total n = 109 isolates). MIC: minimum 
inhibitory concentration, HLGR: high level gentamicin resistance.
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